Clinical trial
A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia
NCT00111683 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2005
- Completion date
- May 31, 2008
- Enrollment
- 28 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic myelogenous leukemia in blast crisis, lymphocytic leukemia, b cell, acute, myelodysplastic syndromes, myelogenous leukemia, chronic